Currently, three CDK4/6 inhibitors, Palbociclib, Ribociclib, and abemaciclib, have been approved by the FDA to treat hormone receptor-positive, HER2-negative advanced breast cancer [4,5,6]. Here, NR4A1 is linked to breast cancer.